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Combined therapyPlasma cell tumors are a heterogeneous group of neoplasms
that includes multiple and isolated plasmacytomas and other
immunoproliferative diseases. An extremely uncommon form
of the disease are solitary extramedullary plasmacytomas
(SEPs) of the central nervous system (CNS) which account for
less than 1% of all malignant tumors and about 14% of
hematological malignancies.
A 37-year-old man came to the casualty department due to
generalized seizures and a several-week history of a numbness
of the left shoulder and left upper limb. Apart from severe
obesity (weight 140 kg), he was otherwise healthy. Computed
tomography (CT) of the head revealed a contrast-enhanced
mass of 2.5 cm in diameter with surrounding edema in the
right hemisphere. The patientwas administeredananti-edema
treatment and a control CT revealed a contrast-enhancing
mass with dimensions of 37 mm  32 mm  36 mm sur-
[(Fig._1)TD$FIG]
Fig. 1 – (A) CT scan showing contrast-enhanced tumor surrounde
the tumor (100T). (C) MRI after tumor resection showing surgical
CT scan showing enhanced glucose uptake at the site of tumorrounded by extensive edema (Fig. 1A) which strongly suggested
glioblastomamultiforme (GBM). Due to the radiological picture
and the lack of response to the anti-edematous treatment the
patient was referred to the urgent surgery (radical resection of
the tumor) without any other preliminary diagnostics (MRI or
biopsy). Surprisingly, the histopathological examination of the
surgical specimen revealed the features of plasmacytoma
showing immunoreactivity for CD138 (Fig. 1B), CD79A, CD3,
GFAP, Ki67, vimentin, and CD10 and no reactivity for CD20,
BCL6 and CD31. The bonemarrow biopsy, bone scintigraphy as
well as blood (calcium, b2-microglobulin, albumin, M-protein)
and urine (M-protein) tests did not show any pathology.
Three months after the resection a control magnetic
resonance imaging (MRI) of the head showed a 23 mm  16
mm  21 mm tumor with an irregular marginal contrast
enhancement corresponding to either post-operative changes
or a residual/recurrent mass (Fig. 1C). The positron emission
tomography with 2-deoxy-2-[ﬂuorine-18]-ﬂuoro-D-glucose in-
tegratedwith the computed tomography (18F-FDG PET/CT) did
not reveal any other CNS pathology except of an enhanced
glucose uptake (SUV 1.5) around the mass which indicated
post-operative changes (Fig. 1D).
The patient was scheduled for radiotherapy to the volume
of the post-operative pathologicalmass (contrast enhanced ond by an extensive edematous zone. (B) CD138 expression in
bed and irregular marginal contrast enhancement. (D) PET-
resection.
Table 1 – Clinical data of patients presenting with intracranial plasmocytoma.
Age(years)/sex Symptoms Localization Treatment Bone
ﬂap inv.
Progression
to MM
Follow-up Ref.
50/F Motor aphasia Left temporal lobe and
thalamus
RT alone No No 48 mos [48_TD$DIFF] 1]
51/F Diplopia Pituitary/sphenoid Surgery + RT No No 8 yrs [49_TD$DIFF] 5]
51/F Mental status change Left parietal lobe Surgery + RT Yes No 2 yrs [49_TD$DIFF] 5]
43/F Headache Falx Surgery + RT No No 8 yrs [49_TD$DIFF] 5]
30/M Headache
6th nerve palsy
Clivus-dural Surgery + RT Yes Yes 3 mos [49_TD$DIFF] 5]
47/M Headache Right parietal lobe Surgery + RT Yes No 25 yrs [49_TD$DIFF] 5]
65/M Hemiparesis Right parietal lobe Surgery alone No No 1 mo [49_TD$DIFF] 5]
75/M Vertigo, hoarseness,
swallowing difﬁculty
Left posterior Surgery + RT Yes Yes 4 yrs [49_TD$DIFF] 5]
82/F Mental status change Left parietal lobe Surgery alone Yes Yes 6 mos [49_TD$DIFF] 5]
64/M Seizures, hemiparesis (1) Frontal mass adjacent
to the cerebral falx
(2) In diploe
Surgery + RT Yes Yes 5 mos [50_TD$DIFF] 6]
37/M Seizures, hemiparesis Right temporal lobe Surgery + RT No No 26 mos Our study
Abbreviation: RT – radiation therapy.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 5 4 3 – 5 4 5544MRI and of increased tracer uptake in 18F-FDG PET/CT) with a
2 cmmargin of normal tissues and irradiatedwith 6 MVX-rays
to a total dose of 45 Gy in 28 fractions. At the admission to the
radiotherapy department, after a several week rehabilitation
the patient's performance status was good (KPS 100) and did
not change during irradiation. The treatment tolerance was
monitored weekly based on the EORTC/RTOG post-radiation
complications scale. At the completion of radiotherapy the
skin reaction was estimated as a 1st degree complication; the
CNS, eyes and cochlea did not present any acute complications
(EORTC/RTOG-0). During a 26-month follow-up (to the last
control visit) the control MRI was conducted every 3 months
and did not reveal any tumor progression.
SEPs occur markedly less frequently than solitary plasmacy-
tomas of the bone (SPBs) [55_TD$DIFF] 1] and very rarely (15%) progress into
multiple plasmacytoma [56_TD$DIFF] 2]. Most SEPs (about 80%) involve the
upper respiratory tract. The gastrointestinal tract, lymph nodes
and urinary bladder are less frequent sites [57_TD$DIFF] 3]. CNS SEPs are
extremely infrequent [58_TD$DIFF] 4] with only individual cases and small
series reported. A systematic review of published cases is
presented in Table 1. They may involve the meninges, parietal
bonesandskull base fromwhere theymayspread toor compress
cerebral tissues. CNS SEPs not arising from the endocranium are
casuistic cases, probably due to the fact that plasma cells are not
found inbrain tissuesundernormal conditions [59_TD$DIFF] 1,7]. SEPsusually
present radiologically as well-separated masses located around
the dura mater or skull base with a homogeneous contrast
enhancement and occasional calciﬁcations. In contrast to
meningiomas they are often located extra-axially [60_TD$DIFF] 7].
In our patient radiological features of a tumor indicated
glioblastoma rather than meningioma. Only one similar case
of a 50-year-old female has been reported. She experienced a
sudden motor aphasia and MRI of the brain showed an
inﬁltrative contrast-enhancing tissue in the left temporal-
insular lobe and thalamuswith surrounding edema and amild
axial median shift. The malignancy inﬁltrated also the corpus
callosum and diffused to the white matter of the right
hemisphere. The brain biopsy and immunohistochemistry
analysis revealed CD138+ elements expressing k light-chainrestriction which conﬁrmed the presence of a mature plasma
cell neoplasm. The patient received whole brain radiotherapy
with 36 Gy plus a 9 Gy boost in the area of the lesion. During a
48-month follow up period there was no evidence of the
disease progression [61_TD$DIFF] 1].
Surgery is currently a treatment of choice and typically no
prior biopsy is performed when an intracranial mass is
considered resectable. However, Provenzale et al. suggested
that a pre-operative biopsy spares in SEPs an unnecessary
resection. Plasmacytomas are relatively highly radio-sensitive
malignancies thus SEPs patients are better candidates for
radiotherapy [62_TD$DIFF] 7]. Nevertheless, three patients in another case
series recovered after either radical or subtotal resection of CNS
SEPs although two of them did not receive adjuvant radiother-
apy [63_TD$DIFF] 5]. Our experience suggests that some CNS SEPs indicate
radiologically other malignancies and, consequently, an elec-
tive surgery is appropriate in patients with resectable lesions.
Radiotherapy is a well-established adjuvant treatment but
should also be considered a radical treatment for non-resectable
tumors [56_TD$DIFF] 2]. A dose–response relationship has not been unequiv-
ocally established.The literature suggests 40 Gy in20 fractionsas
an optimal dose in tumorsmeasuring less than 5 cm in diameter
and 50 Gy in 25 fractions for larger masses [64_TD$DIFF] 8].
The irradiated volume usually includes the mass or its
surgical bed with a 2–3 cm margin [57_TD$DIFF] 3]. Radical whole-brain
radiotherapywith a total dose of 36 Gy andup to 45 Gy boost to
the tumor can be considered in patients with diffuse lesions or
in those ineligible for a surgery [65_TD$DIFF] 1].
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